ArticleNature communications2026
Glucose-induced histone lactylation confers metformin resistance in colorectal cancer stem cells.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) can adapt their metabolism, which limits the effectiveness of therapies targeting metabolic pathways. Here we show that high glucose conditions promote metformin resistance in CD133⁺ colorectal CSCs by driving a switch from glucose dependence to lipid use. Mechanistically, metformin increases LDHA-dependent lactate production in these cells under high glucose conditions. Lactate accumulation enhances histone H3 lysine 18 lactylation (H3K18la), which activates c-JUN and induces CD36 expression. CD36 promotes free fatty acid (FFA) uptake and lipid droplet (LD) formation, providing fuel for fatty acid β-oxidation. This process generates ATP and NADPH, reduces energy stress and reactive oxygen species, and thereby supports CSC survival during metformin treatment. In vitro and in vivo, inhibition of either LDHA or CD36 restores metformin sensitivity in CD133⁺ colorectal CSCs. These findings identify a lactate-driven epigenetic and metabolic pathway underlying metformin resistance and suggest LDHA and CD36 as potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.